Literature DB >> 25656413

Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort.

Renée T Fortner1, Jennifer Ose1, Melissa A Merritt2, Helena Schock1, Anne Tjønneland3, Louise Hansen3, Kim Overvad4, Laure Dossus5,6,7, Françoise Clavel-Chapelon5,6,7, Laura Baglietto8,9, Heiner Boeing10, Antonia Trichopoulou11,12,13, Vassiliki Benetou13, Pagona Lagiou12,13,14, Claudia Agnoli15, Amalia Mattiello16, Giovanna Masala17, Rosario Tumino18, Carlotta Sacerdote19, H B As Bueno-de-Mesquita2,20,21,22, N Charlotte Onland-Moret23, Petra H Peeters23, Elisabete Weiderpass24,25,26,27, Inger Torhild Gram24, Eric J Duell28, Nerea Larrañaga29,30, Eva Ardanaz30,31, María-José Sánchez30,32, M-D Chirlaque30,33, Jenny Brändstedt34,35, Annika Idahl36,37, Eva Lundin38,39, Kay-Tee Khaw40, Nick Wareham41, Ruth C Travis42, Sabina Rinaldi43, Isabelle Romieu43, Marc J Gunter2, Elio Riboli2, Rudolf Kaaks1.   

Abstract

Whether risk factors for epithelial ovarian cancer (EOC) differ by subtype (i.e., dualistic pathway of carcinogenesis, histologic subtype) is not well understood; however, data to date suggest risk factor differences. We examined associations between reproductive and hormone-related risk factors for EOC by subtype in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Among 334,126 women with data on reproductive and hormone-related risk factors (follow-up: 1992-2010), 1,245 incident cases of EOC with known histology and invasiveness were identified. Data on tumor histology, grade, and invasiveness, were available from cancer registries and pathology record review. We observed significant heterogeneity by the dualistic model (i.e., type I [low grade serous or endometrioid, mucinous, clear cell, malignant Brenner] vs. type II [high grade serous or endometrioid]) for full-term pregnancy (phet  = 0.02). Full-term pregnancy was more strongly inversely associated with type I than type II tumors (ever vs. never: type I: relative risk (RR) 0.47 [95% confidence interval (CI): 0.33-0.69]; type II, RR: 0.81 [0.61-1.06]). We observed no significant differences in risk in analyses by major histologic subtypes of invasive EOC (serous, mucinous, endometrioid, clear cell). None of the investigated factors were associated with borderline tumors. Established protective factors, including duration of oral contraceptive use and full term pregnancy, were consistently inversely associated with risk across histologic subtypes (e.g., ever full-term pregnancy: serous, RR: 0.73 [0.58-0.92]; mucinous, RR: 0.53 [0.30-0.95]; endometrioid, RR: 0.65 [0.40-1.06]; clear cell, RR: 0.34 [0.18-0.64]; phet  = 0.16). These results suggest limited heterogeneity between reproductive and hormone-related risk factors and EOC subtypes.
© 2015 UICC.

Entities:  

Keywords:  dualistic model; histologic subtype; ovarian cancer; reproductive factors

Mesh:

Substances:

Year:  2015        PMID: 25656413      PMCID: PMC6284794          DOI: 10.1002/ijc.29471

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Modeling effects of age at and time since delivery on subsequent risk of cancer.

Authors:  I Heuch; G Albrektsen; G Kvåle
Journal:  Epidemiology       Date:  1999-11       Impact factor: 4.822

2.  Applying Cox regression to competing risks.

Authors:  M Lunn; D McNeil
Journal:  Biometrics       Date:  1995-06       Impact factor: 2.571

3.  Histologic types of epithelial ovarian cancer: have they different risk factors?

Authors:  Allison W Kurian; Raymond R Balise; Valerie McGuire; Alice S Whittemore
Journal:  Gynecol Oncol       Date:  2005-02       Impact factor: 5.482

Review 4.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

5.  Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness.

Authors:  F Modugno; R B Ness; J E Wheeler
Journal:  Ann Epidemiol       Date:  2001-11       Impact factor: 3.797

6.  Parity, age at first childbirth, and risk of ovarian cancer.

Authors:  H O Adami; C C Hsieh; M Lambe; D Trichopoulos; D Leon; I Persson; A Ekbom; P O Janson
Journal:  Lancet       Date:  1994-11-05       Impact factor: 79.321

Review 7.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

8.  Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study.

Authors:  Ko-Hui Tung; Marc T Goodman; Anna H Wu; Katharine McDuffie; Lynne R Wilkens; Laurence N Kolonel; Abraham M Y Nomura; Keith Y Terada; Michael E Carney; Leslie H Sobin
Journal:  Am J Epidemiol       Date:  2003-10-01       Impact factor: 4.897

9.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection.

Authors:  E Riboli; K J Hunt; N Slimani; P Ferrari; T Norat; M Fahey; U R Charrondière; B Hémon; C Casagrande; J Vignat; K Overvad; A Tjønneland; F Clavel-Chapelon; A Thiébaut; J Wahrendorf; H Boeing; D Trichopoulos; A Trichopoulou; P Vineis; D Palli; H B Bueno-De-Mesquita; P H M Peeters; E Lund; D Engeset; C A González; A Barricarte; G Berglund; G Hallmans; N E Day; T J Key; R Kaaks; R Saracci
Journal:  Public Health Nutr       Date:  2002-12       Impact factor: 4.022

10.  Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004.

Authors:  Stalo Karageorgi; Susan E Hankinson; Peter Kraft; Immaculata De Vivo
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

View more
  26 in total

1.  Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.

Authors:  Camilla Sköld; Tone Bjørge; Anders Ekbom; Anders Engeland; Mika Gissler; Tom Grotmol; Laura Madanat-Harjuoja; Anne Gulbech Ording; Olof Stephansson; Britton Trabert; Steinar Tretli; Rebecca Troisi; Henrik Toft Sørensen; Ingrid Glimelius
Journal:  Int J Cancer       Date:  2018-07-10       Impact factor: 7.396

2.  Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Louise A Brinton; Garnet L Anderson; Ruth M Pfeiffer; Roni T Falk; Howard D Strickler; Sarunas Sliesoraitis; Lewis H Kuller; Margery L Gass; Barbara J Fuhrman; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-05       Impact factor: 4.254

3.  Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression.

Authors:  Holly R Harris; Megan S Rice; Amy L Shafrir; Elizabeth M Poole; Mamta Gupta; Jonathan L Hecht; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-13       Impact factor: 4.254

4.  Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium.

Authors:  Jennifer Ose; Elizabeth M Poole; Helena Schock; Matti Lehtinen; Alan A Arslan; Anne Zeleniuch-Jacquotte; Kala Visvanathan; Kathy Helzlsouer; Julie E Buring; I-Min Lee; Anne Tjønneland; Laure Dossus; Antonia Trichopoulou; Giovanna Masala; N Charlotte Onland-Moret; Elisabete Weiderpass; Eric J Duell; Annika Idahl; Ruth C Travis; Sabina Rinaldi; Melissa A Merritt; Britton Trabert; Nicolas Wentzensen; Shelley S Tworoger; Rudolf Kaaks; Renée T Fortner
Journal:  Cancer Res       Date:  2017-04-05       Impact factor: 12.701

5.  A prospective study of reproductive factors and exogenous hormone use in relation to ovarian cancer risk among Black women.

Authors:  Traci N Bethea; Julie R Palmer; Lucile L Adams-Campbell; Lynn Rosenberg
Journal:  Cancer Causes Control       Date:  2016-12-27       Impact factor: 2.506

6.  Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Sally B Coburn; Roni T Falk; JoAnn E Manson; Louise A Brinton; Margery L Gass; Lewis H Kuller; Thomas E Rohan; Ruth M Pfeiffer; Lihong Qi; Marcia L Stefanick; Nicolas Wentzensen; Garnet L Anderson; Xia Xu
Journal:  Cancer Causes Control       Date:  2019-09-21       Impact factor: 2.506

7.  Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort.

Authors:  Mireia Obón-Santacana; Heinz Freisling; Petra H Peeters; Leila Lujan-Barroso; Pietro Ferrari; Marie-Christine Boutron-Ruault; Sylvie Mesrine; Laura Baglietto; Renee Turzanski-Fortner; Verena A Katzke; Heiner Boeing; J Ramón Quirós; Elena Molina-Portillo; Nerea Larrañaga; María-Dolores Chirlaque; Aurelio Barricarte; Kay-Tee Khaw; Nick Wareham; Ruth C Travis; Melissa A Merritt; Marc J Gunter; Antonia Trichopoulou; Pagona Lagiou; Androniki Naska; Domenico Palli; Sabina Sieri; Rosario Tumino; Valentina Fiano; Rocco Galassom; H B As Bueno-de-Mesquita; N Charlotte Onland-Moret; Annika Idahl; Eva Lundin; Elisabete Weiderpass; Hubert Vesper; Elio Riboli; Eric J Duell
Journal:  Int J Cancer       Date:  2015-10-01       Impact factor: 7.396

8.  Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.

Authors:  Nicolas Wentzensen; Elizabeth M Poole; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Lesley M Butler; Saioa Chamosa; Tess V Clendenen; Laure Dossus; Renee Fortner; Susan M Gapstur; Mia M Gaudet; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Michael Jones; Rudolf Kaaks; Victoria Kirsh; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Louise K Sjöholm; Sabina Sieri; Anthony Swerdlow; Anna Tjonneland; Ruth Travis; Antonia Trichopoulou; Piet A van den Brandt; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 9.  Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer.

Authors:  William V Williams; Louise A Mitchell; S Kathleen Carlson; Kathleen M Raviele
Journal:  Linacre Q       Date:  2019-01-03

10.  Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case-Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort.

Authors:  Mireia Obón-Santacana; Leila Lujan-Barroso; Ruth C Travis; Heinz Freisling; Pietro Ferrari; Gianluca Severi; Laura Baglietto; Marie-Christine Boutron-Ruault; Renée T Fortner; Jennifer Ose; Heiner Boeing; Virginia Menéndez; Emilio Sánchez-Cantalejo; Saioa Chamosa; José María Huerta Castaño; Eva Ardanaz; Kay-Tee Khaw; Nick Wareham; Melissa A Merritt; Marc J Gunter; Antonia Trichopoulou; Eleni-Maria Papatesta; Eleni Klinaki; Calogero Saieva; Giovanna Tagliabue; Rosario Tumino; Carlotta Sacerdote; Amalia Mattiello; H B Bueno-de-Mesquita; Petra H Peeters; N Charlotte Onland-Moret; Annika Idahl; Eva Lundin; Elisabete Weiderpass; Hubert W Vesper; Elio Riboli; Eric J Duell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-23       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.